Using existing clinical trial data to proactively model patient safety and efficacy outcomes could aid in accelerating development for areas in need of new therapies.
Peter M. O’Neill
Advertisement
Articles by Peter M. O’Neill
Advertisement
Latest Updated Articles
Lightship’s Approach to Accessible, Representative, and Impactful Clinical TrialsPublished: February 13th 2025 | Updated: March 4th 2025
Accelerate Inclusive Enrollment and Delivery with LightshipPublished: February 19th 2025 | Updated: February 26th 2025
Examining the Impact of Exclusionary Behaviors on Team DynamicsPublished: March 24th 2023 | Updated:
Trials and Tribulations of Electronic Patient Consent: Removing Barriers to eConsent AdoptionPublished: April 28th 2021 | Updated:
Sticking to the Plan: Undue Burden Created by Protocol DeviationsPublished: July 26th 2024 | Updated:
Phase III PERSEUS Trial Data Show Darzalex Faspro Combo Improves Survival in Newly Diagnosed Multiple MyelomaPublished: January 31st 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
3
eClinical Technology: Misconceptions, Challenges, and Opportunities
4
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
